GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Amoy Diagnostics Co Ltd (SZSE:300685) » Definitions » Debt-to-EBITDA

Amoy Diagnostics Co (SZSE:300685) Debt-to-EBITDA : 0.17 (As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Amoy Diagnostics Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Amoy Diagnostics Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was ¥54 Mil. Amoy Diagnostics Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was ¥4 Mil. Amoy Diagnostics Co's annualized EBITDA for the quarter that ended in Jun. 2024 was ¥340 Mil. Amoy Diagnostics Co's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 was 0.17.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Amoy Diagnostics Co's Debt-to-EBITDA or its related term are showing as below:

SZSE:300685' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.02   Med: 0.09   Max: 0.82
Current: 0.18

During the past 12 years, the highest Debt-to-EBITDA Ratio of Amoy Diagnostics Co was 0.82. The lowest was 0.02. And the median was 0.09.

SZSE:300685's Debt-to-EBITDA is ranked better than
89.22% of 102 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.565 vs SZSE:300685: 0.18

Amoy Diagnostics Co Debt-to-EBITDA Historical Data

The historical data trend for Amoy Diagnostics Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amoy Diagnostics Co Debt-to-EBITDA Chart

Amoy Diagnostics Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.02 0.02 0.16 0.16

Amoy Diagnostics Co Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 0.26 0.14 0.19 0.17

Competitive Comparison of Amoy Diagnostics Co's Debt-to-EBITDA

For the Diagnostics & Research subindustry, Amoy Diagnostics Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amoy Diagnostics Co's Debt-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Amoy Diagnostics Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Amoy Diagnostics Co's Debt-to-EBITDA falls into.



Amoy Diagnostics Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Amoy Diagnostics Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(10.115 + 46.567) / 352.598
=0.16

Amoy Diagnostics Co's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(53.574 + 3.747) / 340.24
=0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2024) EBITDA data.


Amoy Diagnostics Co  (SZSE:300685) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Amoy Diagnostics Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Amoy Diagnostics Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Amoy Diagnostics Co Business Description

Traded in Other Exchanges
N/A
Address
39 Dingshan Road, Haicang District, Xiamen, CHN, 361027
Amoy Diagnostics Co Ltd is the pharmaceutical company based in China. The company primarily focuses on molecular diagnostics for oncology precision medicine. It provides diagnostic products and services for medicine development and clinical oncology practice. The company's products include gene mutation, nucleic acid extraction, and molecular diagnostic kits comprising EGFR, RAS, ALK, BRAF, PIK3CA, and ROS1 testing kits.
Executives
Ruan Li Directors, executives
Zheng Hui Bin Directors, executives
Chen Ying Directors, executives
Luo Jie Min Executives
Zhu Guan Shan Directors, executives
Yang Shou Qian Securities Affairs Representative
Zhou Wen Gang Executives
Zhou Xue Lin Independent director
Hu Xu Bo Director

Amoy Diagnostics Co Headlines

No Headlines